Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.

Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang ZD, Dupont HL, Garneau P, Harel J, Rishniw M, Simpson KW.

Inflamm Bowel Dis. 2013 Jan;19(1):141-50. doi: 10.1002/ibd.22971.

PMID:
22508665
2.

Microbial exposure during early life has persistent effects on natural killer T cell function.

Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, Blumberg RS.

Science. 2012 Apr 27;336(6080):489-93. doi: 10.1126/science.1219328. Epub 2012 Mar 22.

3.

Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.

Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P; Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease).

Gastroenterology. 2012 Mar;142(3):473-481.e4. doi: 10.1053/j.gastro.2011.11.032. Epub 2011 Dec 6.

PMID:
22155172
4.

Induction of colonic regulatory T cells by indigenous Clostridium species.

Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K.

Science. 2011 Jan 21;331(6015):337-41. doi: 10.1126/science.1198469. Epub 2010 Dec 23.

5.

Impact of Clostridium difficile on inflammatory bowel disease.

Ananthakrishnan AN, Binion DG.

Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):589-600. doi: 10.1586/egh.10.55. Review.

PMID:
20932144
6.

Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases.

Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, Zhu W, Sartor RB, Boedeker EC, Harpaz N, Pace NR, Li E.

Inflamm Bowel Dis. 2011 Jan;17(1):179-84. doi: 10.1002/ibd.21339. Epub 2010 Sep 13.

7.

A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes.

Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L.

Gastroenterology. 2010 Dec;139(6):1844-1854.e1. doi: 10.1053/j.gastro.2010.08.049. Epub 2010 Oct 8.

PMID:
20816835
8.

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.

Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P.

Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6. doi: 10.1073/pnas.0804812105. Epub 2008 Oct 20.

9.

Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease.

Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM.

Aliment Pharmacol Ther. 2008 Jun;27(12):1233-9. doi: 10.1111/j.1365-2036.2008.03661.x. Epub 2008 Feb 27.

10.

Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum.

Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW.

ISME J. 2007 Sep;1(5):403-18. Epub 2007 Jul 12.

PMID:
18043660
11.

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.

Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR.

Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13780-5. Epub 2007 Aug 15.

12.

Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.

Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D; Antibiotics in Crohn's Disease Study Group.

Gastroenterology. 2007 Jun;132(7):2313-9. Epub 2007 Mar 21.

PMID:
17570206
13.

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M.

Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25.

14.

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.

Scarpignato C, Pelosini I.

Digestion. 2006;73 Suppl 1:13-27. Epub 2006 Feb 8. Review.

PMID:
16498249
15.

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.

Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR.

Gastroenterology. 2002 Jul;123(1):33-40.

PMID:
12105831
16.

Preliminary study of ciprofloxacin in active Crohn's disease.

Arnold GL, Beaves MR, Pryjdun VO, Mook WJ.

Inflamm Bowel Dis. 2002 Jan;8(1):10-5.

PMID:
11837933
17.

Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.

Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C.

Am J Gastroenterol. 1994 Apr;89(4):513-8.

PMID:
8147352
18.

Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo.

Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP.

Dig Dis Sci. 1991 Apr;36(4):449-53.

PMID:
2007362
19.

Double blind, placebo controlled trial of metronidazole in Crohn's disease.

Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, et al.

Gut. 1991 Sep;32(9):1071-5.

Supplemental Content

Support Center